Abstract
Purpose: We examined the physiological effects and tolerance of UroPhos- K,|| a slow release neutral form of potassium phosphate (155 mg. phosphate and 8 mEq. potassium per tablet) in patients with absorptive hypercalciuria. Materials and Methods: A total of 31 patients with absorptive hypercalciuria were studied at baseline and after 3 months of treatment with 4 tablets twice daily of UroPhos-K or placebo (identical in appearance) in a prospective randomized, placebo controlled, double-blind trial during a 4-day inpatient study with a daily constant metabolic diet containing 400 mg. calcium, 100 mEq. sodium and 800 mg. phosphate. Results: Treatment with UroPhos-K did not cause significant gastrointestinal side effects, increase fasting serum potassium or phosphorus, or reduce hemoglobin or creatinine clearance. It reduced urinary calcium excretion from 277 ± 72 to 166 ± 43 mg. per day (p <0.001), associated with a reduction in serum 1,25-dihydroxyvitamin D concentration from 50 ± 11 to 42 ± 9 pg./ml. (p <0.001). Indexes of intestinal calcium absorption and markers of bone turnover also decreased modestly. None of these changes was seen in the placebo group. Conclusions: In patients with absorptive hypercalciuria UroPhos-K seems to correct hypercalciuria by a combination of reduced intestinal absorption, bone resorption and improved renal calcium reabsorption. The drug is well tolerated compared to placebo.
Original language | English (US) |
---|---|
Pages (from-to) | 664-668 |
Number of pages | 5 |
Journal | Journal of Urology |
Volume | 160 |
Issue number | 3 I |
DOIs | |
State | Published - Sep 1998 |
Keywords
- Calcium
- Delayed-action preparations
- Phosphates
- Randomized controlled trials
- Urinary calculi
ASJC Scopus subject areas
- Urology